Dopamine Hydrochloride Articles
Drug candidates in pipeline offer potential for Parkinson's disease market, says Frost & Sullivan
9 December 2009
Watson buy of Arrow requires product divestments, says USA’s FTC
4 December 2009
Servier’s Valdoxan superior to Prozac for severe depression in adults
19 September 2009
Safinamide enters Ph III SETTLE trial
11 May 2009
Acadia and Meiji Seika to co-develop pro-cognitive drugs
30 March 2009
p11 shows rapid antidepressant effect
30 March 2009
Toxoplasmosis linked to schizophrenia
16 March 2009
Azilect helps "double 2nd-line MAO-Bs in PD"
16 March 2009
AstraZeneca licenses preclinical-stage TRIs
16 February 2009
Rexahn initiates Ph IIa MDD study of Serdaxin
9 February 2009
Japan's development of Xenazine urged
12 January 2009
Synosia initiates proof-of-concept nitisinone study in RLS
22 December 2008
Ceregene PD drug fails to beat placebo in trial
1 December 2008
Neurosearch obesity drug fares well in Ph II
10 November 2008
Synosia begins Ph II post-traumatic stress trial
10 November 2008
Top-line Ph II data for Neurogen's aplindore good
20 October 2008
Newron granted European patent for safinamide in RLS
20 October 2008
Forest and Richter report on bipolar trial
6 October 2008
Skyepharma further reduces loss in first half
8 September 2008
Anti-addiction drug may treat obesity
1 September 2008
Neurogen suspends adipiplon in insomnia
21 July 2008
Synosia initiates Ph IIa trial of PD drug
14 July 2008
FDA approval for GSK
23 June 2008
Axxonis submits MAA for Nenad
9 June 2008
Ergonex' Terguride granted Orphan Status for PAH
2 June 2008
GSK launches once-daily ReQuip XL in UK
19 May 2008
Japan stock market week to Apr 28, 2008
5 May 2008
Titan presents follow-up Spheramine data
5 May 2008
Pediatric off-label use of antipsychotic drugs in UK
21 April 2008
Japan stock market week to March 31, 2008
7 April 2008
Newron says EPO will issue safinamide patent for PD
3 March 2008
Florida Detox urges new depression classification
25 February 2008
GSK's Requip Modutab approved in 8 EU countries
17 December 2007
Requip gets US FDA "approvable" letter
17 December 2007
FDA panel advises tetrabenazine approval
17 December 2007
Japan stock market week to Dec 3, 2007
10 December 2007
Merck Serono sets Ph III PD drug trial in MOTION
3 December 2007
Chiesi launches Cambridge Labs' Xenazina in Italy
19 November 2007
Eisai to delay E2007 filing until fiscal 2008
5 November 2007
UCB's Neupro effective for motor impairment in PD
15 October 2007
Research shows pine bark extract reduces ADHD symptoms in children
24 September 2007
Newron opens Swiss R&D center in Basel
10 September 2007
Depression prevalent in PD, says study
10 September 2007
Newron's safinamide misses Ph III efficacy endpoint
3 September 2007
Chiesi wins Italian approval for Cambridge's Xenazina
20 August 2007
US FDA asks for 2nd trial of bifeprunox
20 August 2007
FDA marks Abilify sNDA for priority review
30 July 2007
BioLineRx' antipsychotic to enter Ph II
23 July 2007
Isradipine slows Parkinson's disease
25 June 2007
Safinamide boosts STDT score in PD patients
18 June 2007
BioLineRx begins new BL-1020 study
21 May 2007
Safinamide improves motor symptoms in PD
7 May 2007
GSK/SkyePharma file Requip XL with US FDA
23 April 2007
Cambridge Labs debuts Nitoman in Germany
19 March 2007
BioLineRx's BL-1020 completes Ph I trial
19 February 2007
BI meeting discusses depression's role in PD
19 February 2007
Droxidopa demonstrates benefit in Ph IIb NOH trial
22 January 2007
Schwarz Pharma's rotigotine performs well in PD trial
8 January 2007
Neurogen acquires global Aplindore rights form Wyeth
4 December 2006
OREXIGEN completes $30M financing
27 November 2006
NeuroSearch initiates Ph I ACR325 trial
13 November 2006
No extra AEs for GSK's once-daily PD drug
11 September 2006
Vectura's PD drug successful in Ph II study
14 August 2006
Newron's safinamide shows promise in PD
3 July 2006
Otsuka/B-MS Abilify gains Prix Galien
12 June 2006
GSK's Adartrel gets EU OK for RLS
17 April 2006
GSK's ReQuip fares well vs Schwarz' Neupro
17 April 2006
Schwarz' Neupro launched in the UK
10 April 2006
Schwarz' Neupro launched in the UK
10 April 2006
Prestwick's Xenazine receives FDA approvable letter
10 April 2006
Biofusion debuts Genophrenix, its spin-out for neuropsychiatry
27 February 2006
Solvay's 2005 revenue reaches 8.5 B euros
27 February 2006
Xenazine performs well in HD study
27 February 2006
Prestwick's tetrabenazine shows benefits in Huntington's
20 February 2006
Strong animal data for KDI in PD
5 December 2005
Biogen Idec seeks PD treatment in NgR1
5 December 2005
GSK EPS rises 10% on 6% sales growth
8 August 2005
GlaxoSmithKline sees 10% EPS rise on 6% sales growth
1 August 2005
Takeda R&D meeting focuses on insomnia treatment Rozeram
1 August 2005
BI's pramipexole shows promise as RLS therapy
4 July 2005
UK experts back Abilify for schizophrenia
16 May 2005
DOV initiates Phase I trial of depression drug
7 March 2005
Potential drug target for cocaine abuse found
7 March 2005
Avigen initiates Ph I/II trial of AV201
10 January 2005
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
